Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to $304.3 million.

  • Sangamo Therapeutics' Shares Outstanding (Weighted Average) rose 4605.58% to $304.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $304.3 million, marking a year-over-year increase of 4605.58%. This contributed to the annual value of $201.7 million for FY2024, which is 1562.39% up from last year.
  • Sangamo Therapeutics' Shares Outstanding (Weighted Average) amounted to $304.3 million in Q3 2025, which was up 4605.58% from $257.0 million recorded in Q2 2025.
  • Over the past 5 years, Sangamo Therapeutics' Shares Outstanding (Weighted Average) peaked at $304.3 million during Q3 2025, and registered a low of $143.1 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $181.8 million, with a median of $174.3 million in 2023.
  • As far as peak fluctuations go, Sangamo Therapeutics' Shares Outstanding (Weighted Average) soared by 217.03% in 2022, and later skyrocketed by 4605.58% in 2025.
  • Quarter analysis of 5 years shows Sangamo Therapeutics' Shares Outstanding (Weighted Average) stood at $144.6 million in 2021, then increased by 6.76% to $154.3 million in 2022, then grew by 13.02% to $174.4 million in 2023, then grew by 15.62% to $201.7 million in 2024, then surged by 50.87% to $304.3 million in 2025.
  • Its last three reported values are $304.3 million in Q3 2025, $257.0 million for Q2 2025, and $220.3 million during Q1 2025.